TABLE II.
Univariate analysis for predictors of publication in journals with a higher impact factor
| Predictor |
Journal category
|
|||||
|---|---|---|---|---|---|---|
|
All topics
|
Oncology only
|
|||||
| or | 95% ci | p Value | or | 95% ci | p Value | |
| Cancer type | 0.030 | 0.84 | ||||
| Common | Reference | Reference | ||||
| Hematologic | 2.04 | 1.03 to 4.04 | 0.81 | 0.31 to 2.08 | ||
| Other | 1.49 | 1.02 to 2.18 | 1.08 | 0.65 to 1.78 | ||
| Type of therapy | <0.001 | 0.56 | ||||
| Chemotherapy | 0.49 | 0.34 to 0.71 | 1.16 | 0.71 to 1.87 | ||
| Intent of therapy | <0.001 | 0.15 | ||||
| Adjuvant | 2.27 | 1.56 to 3.19 | 1.43 | 0.88 to 2.31 | ||
| Sample size | <0.001 | 0.040 | ||||
| Per 100 patients | 1.08 | 1.05 to 1.12 | 1.08 | 1.00 to 1.15 | ||
| Accrual rate | <0.001 | 0.030 | ||||
| Per 100 patients | 1.19 | 1.09 to 1.30 | 1.22 | 1.02 to 1.45 | ||
| Primary endpoint | 0.64 | 1.00 | ||||
| Overall survival | 0.92 | 0.65 to 1.30 | 1.00 | 0.64 to 1.58 | ||
| Independent review committee | 0.56 | 0.059 | ||||
| Yes | 0.89 | 0.61 to 1.31 | 0.63 | 0.38 to 1.02 | ||
| Analysis | <0.001 | 0.014 | ||||
| Intention-to-treat | 2.59 | 1.71 to 3.91 | 1.85 | 1.14 to 3.01 | ||
| Industry-funded | 0.42 | 0.033 | ||||
| Yes | 1.16 | 0.81 to 1.65 | 1.69 | 1.04 to 2.74 | ||
| Nationality of authors | 0.021 | <0.001 | ||||
| North American | Reference | Reference | ||||
| European | 0.55 | 0.37 to 0.83 | 0.17 | 0.08 to 0.35 | ||
| International | 0.85 | 0.48 to 1.50 | 0.34 | 0.14 to 0.86 | ||
| Non-English-speaking | 0.48 | 0.21 to 1.09 | 0.16 | 0.05 to 0.49 | ||
| Publication year | 0.60 | 0.33 | ||||
| Later | 1.02 | 0.96 to 1.08 | 1.04 | 0.96 to 1.12 | ||
| Duration of study | 0.030 | 0.38 | ||||
| Per year | 1.09 | 1.01 to 1.17 | 0.96 | 0.87 to 1.05 | ||
| Outcome | <0.001 | 0.033 | ||||
| Positive | 4.52 | 3.01 to 6.80 | 1.89 | 1.05 to 3.37 | ||
| Time to publication | 0.003 | 0.37 | ||||
| Per year | 0.90 | 0.83 to 0.96 | 0.96 | 0.88 to 1.05 | ||